The antiangiogenic agents or targets of the VEGF pathway, such as the anti-VEGF monoclonal antibodies (Bevacizumab) and tyrosine kinase inhibitors (Sunitinib, Sorafenib), that are prescribed for the treatment of cancer-related conditions or organ rejection in renal transplant patients (Sirolimus) have also been indicated in the pathophysiology of the disease [3]. This evidence concerns the gene VEGFA and cancer.